{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:17:23Z","timestamp":1781921843254,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ygyno.2012.12.004","type":"journal-article","created":{"date-parts":[[2012,12,9]],"date-time":"2012-12-09T15:00:34Z","timestamp":1355065234000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin\/paclitaxel versus placebo in combination with carboplatin\/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)"],"prefix":"10.1016","volume":"130","clinical-trial-number":[{"clinical-trial-number":"nct00554229","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00929162","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"F.","family":"Cognetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.12.004_bb0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","article-title":"Achievements and unmet needs in the management of advanced ovarian cancer","volume":"117","author":"Guarneri","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0029-7844(98)00334-2","article-title":"Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings","volume":"93","author":"Rubin","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0020","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1677\/erc.1.01077","article-title":"Emerging role of the endothelin axis in ovarian tumor progression","volume":"12","author":"Bagnato","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2011.01217.x","article-title":"Role of the endothelin axis and its antagonists in the treatment of cancer","volume":"163","author":"Bagnato","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins","volume":"333","author":"Levin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0040","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-07-0151","article-title":"ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo","volume":"6","author":"Rosan\u00f2","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0045","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1158\/0008-5472.CAN-07-0883","article-title":"Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity","volume":"67","author":"Rosan\u00f2","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1139\/Y10-053","article-title":"Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer","volume":"88","author":"Rosano","year":"2010","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0055","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0065","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1200\/JCO.2001.19.6.1848","article-title":"Clinical trial designs for the early clinical development of therapeutic cancer vaccines","volume":"19","author":"Simon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0070","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1464-410X.2010.09638.x","volume":"106","author":"James","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0075","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1078-0432.CCR-10-2325","article-title":"Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells","volume":"17","author":"Rosano","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0080","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.fertnstert.2005.10.064","article-title":"The play of chance","volume":"85","author":"Collins","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6604373","article-title":"EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality","volume":"99","author":"Milano","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph1411s45","article-title":"Genetically engineered mouse models of ovarian cancer and their utility in drug discovery","author":"Sale","year":"2009","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-2-12","article-title":"Ovarian cancer mouse models: a summary of current models and their limitations","volume":"2","author":"Fong","year":"2009","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0100","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.5858\/133.11.1775","article-title":"Ovarian cancer update: lessons from morphology, molecules, and mice","volume":"133","author":"Cho","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.lfs.2012.03.023","article-title":"The endothelin A receptor and epidermal growth factor receptor signaling converge on beta-catenin to promote ovarian cancer metastasis","volume":"91","author":"Cianfrocca","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0110","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0115","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0120","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 15","key":"10.1016\/j.ygyno.2012.12.004_bb0125","article-title":"Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: FInal data from a multicenter phase II study","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0130","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0135","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"15S","key":"10.1016\/j.ygyno.2012.12.004_bb0140","article-title":"Phase II study of NKTR-102 in women with platinum-resistant\/refractory ovarian cancer","volume":"28","author":"Vergote","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2012.12.004_bb0145","article-title":"A Phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"21","author":"Farley","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0150","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial","volume":"55","author":"James","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/pros.21435","article-title":"Emerging treatment options for patients with castration-resistant prostate cancer","volume":"72","author":"George","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0160","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/1078-0432.CCR-10-0669","article-title":"Analysis of the yield of phase II combination therapy trials in medical oncology","volume":"16","author":"Maitland","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.12.004_bb0165","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812009511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812009511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T16:28:58Z","timestamp":1643819338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812009511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0090825812009511"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969432.793470323","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717969432.793469621","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin\/paclitaxel versus placebo in combination with carboplatin\/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}